Matt Phipps Analyst Performance

Matt Phipps is a stock analyst at William Blair, covering 16 publicly traded companies across a range of sectors. Over the past year, Matt Phipps has issued 6 stock ratings, including buy and hold recommendations. While full access to Matt Phipps' proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt Phipps' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

35 Last 7 Years

Buy Recommendations

85.71% 30 Buy Ratings

Companies Covered

16 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	85.7%	30 ratings
Hold	14.3%	5 ratings
Sell	0.0%	0 ratings

Out of 35 total stock ratings issued by Matt Phipps at William Blair, the majority (85.7%) have been Buy recommendations, followed by 14.3% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  DVAX

  Mar 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  ADRO

  Oct 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	16 companies

Matt Phipps, an analyst at William Blair, currently covers 16 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 16 companies	100.0%

Matt Phipps of William Blair specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 11 companies	68.8%
PHARMACEUTICAL PREPARATIONS 3 companies	18.8%
MED - DRUGS 2 companies	12.5%

Matt Phipps' Ratings History at William Blair

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Time Frame

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
INSM Insmed	8/20/2025	Initiated Coverage	$127.21		Outperform	$0.00 00.00% ROI
INKT MiNK Therapeutics	7/11/2025	Downgrade	$64.17		Market Perform	$0.00 00.00% ROI
JSPR Jasper Therapeutics	7/7/2025	Reiterated Rating	$3.27		Market Perform	$0.00 00.00% ROI
CNTX Context Therapeutics	4/21/2025	Initiated Coverage	$0.84		Outperform	$0.00 00.00% ROI
XNCR Xencor	4/21/2025	Initiated Coverage	$9.70		Outperform	$0.00 00.00% ROI
GMAB Genmab A/S	3/11/2025	Upgrade	$21.98		Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.